Literature DB >> 20410227

A consensus on criteria for cure of acromegaly.

A Giustina1, P Chanson, M D Bronstein, A Klibanski, S Lamberts, F F Casanueva, P Trainer, E Ghigo, K Ho, S Melmed.   

Abstract

OBJECTIVE: The Acromegaly Consensus Group met in April 2009 to revisit the guidelines on criteria for cure as defined in 2000. PARTICIPANTS: Participants included 74 neurosurgeons and endocrinologists with extensive experience of treating acromegaly. EVIDENCE/CONSENSUS PROCESS: Relevant assays, biochemical measures, clinical outcomes, and definition of disease control were discussed, based on the available published evidence, and the strength of consensus statements was rated.
CONCLUSIONS: Criteria to define active acromegaly and disease control were agreed, and several significant changes were made to the 2000 guidelines. Appropriate methods of measuring and achieving disease control were summarized.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20410227     DOI: 10.1210/jc.2009-2670

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  226 in total

1.  Biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients.

Authors:  Mai Christiansen Arlien-Søborg; Christian Trolle; Elin Alvarson; Amanda Bæk; Jakob Dal; Jens Otto Lunde Jørgensen
Journal:  Endocrine       Date:  2017-03-04       Impact factor: 3.633

2.  Pre-surgical treatment with somatostatin analogues in patients with acromegaly: the case against.

Authors:  M Losa; V G Crippa
Journal:  J Endocrinol Invest       Date:  2012-06       Impact factor: 4.256

3.  Pituitary gland: New consensus in acromegaly: criteria for cure and control.

Authors:  Nienke Biermasz
Journal:  Nat Rev Endocrinol       Date:  2010-09       Impact factor: 43.330

4.  Assessment of sleep apnea syndrome in treated acromegalic patients and correlation of its severity with clinical and laboratory parameters.

Authors:  L Vannucci; P Luciani; E Gagliardi; S Paiano; R Duranti; G Forti; A Peri
Journal:  J Endocrinol Invest       Date:  2012-07-09       Impact factor: 4.256

5.  Bone histomorphometry in acromegaly patients with fragility vertebral fractures.

Authors:  L Dalle Carbonare; V Micheletti; E Cosaro; M T Valenti; M Mottes; G Francia; M V Davì
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

6.  Voice characteristics of acromegaly.

Authors:  Kadriye Aydin; Didem Turkyilmaz; Burak Ozturk; Selcuk Dagdelen; Burce Ozgen; Faruk Unal; Tomris Erbas
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-02-07       Impact factor: 2.503

7.  Self-perception of cognitive function among patients with active acromegaly, controlled acromegaly, and non-functional pituitary adenoma: a pilot study.

Authors:  Chris G Yedinak; Maria Fleseriu
Journal:  Endocrine       Date:  2013-11-27       Impact factor: 3.633

8.  Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.

Authors:  Sabrina Chiloiro; Gherardo Mazziotti; Antonella Giampietro; Antonio Bianchi; Stefano Frara; Marilda Mormando; Alfredo Pontecorvi; Andrea Giustina; Laura De Marinis
Journal:  Pituitary       Date:  2018-06       Impact factor: 4.107

9.  Elevated intraocular pressure in patients with acromegaly.

Authors:  Luciano Quaranta; Ivano Riva; Gherardo Mazziotti; Teresa Porcelli; Irene Floriani; Andreas Katsanos; Andrea Giustina; Anastasios G P Konstas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-10       Impact factor: 3.117

Review 10.  The role of combination medical therapy in the treatment of acromegaly.

Authors:  Dawn Shao Ting Lim; Maria Fleseriu
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.